Drug Formulation & Delivery: Oral GLP 1 Systems
AGENDA OVERVIEW
4pm UK Time - 20-minute Interview with Andreas Bernkop‑Schnürch
4.20 pm UK Time - Panel Discussion: Overcoming Scientific and Technological Challenges Of Formulating Oral GLP-1 Therapies
This panel will explore the scientific and technological challenges of formulating oral GLP-1 therapies, including absorption enhancement, stability, bioavailability, and patient-centric design
- Formulation Strategies
- Emerging delivery platforms
- Blood Brain Barrier challenges
- Translational hurdles
- Future directions shaping next-generation oral peptide therapeutics.
Moderator: Andreas Bernkop‑Schnürch, Professor, University of Innsbruck, Austria
Panellists:
- Jitendra Kumar, Lead Scientist, Entos Pharma
- Severin Schneebeli, Associate Professor, Organic Chemistry, Industrial and Molecular Pharmaceutics
- Vivek Gupta, Associate Professor, Pharmaceutical Sciences, St. John's University College of Pharmacy
Biography:
Andreas Bernkop-Schnürch is a leading scientist in the field of drug delivery focusing on mucoadhesive polymers such as in particular thiomers, non-invasive peptide delivery systems and nanoemulsions.
He is chairman at the Department of Pharmaceutical Technology at the University of Innsbruck, Austria and CSO of the drug delivery company ThioMatrix GmbH. He has published more than 500 research and review articles.
How to translate organ-chips to reduce the use of animals and accelerate therapeutic delivery
AGENDA OVERVIEW
1:30 PM Thought Leader Interview with Martin Knight
1:50 PM Panel Discussion: How To Translate Organ-chips To Reduce The Use Of Animals And Accelerate Therapeutic Delivery
Where OoC delivers real value
- Which drug discovery decisions benefit most from OoC today?
- What level of standardisation is essential for adoption?
- Translating organ-chips to reduce the use of animals and accelerate therapeutic delivery
- Regulatory and future outlook
Panellists
Prof Hazel Screen, Professor of Biomedical Engineering, Queen Mary University of London
Helena Rannikmae, Scientific Leader, Translational In Vitro Models, GlaxoSmithKline
Emily Richardson, Lead Scientist R&D, CN Bio
Biography:
Prof Martin Knight is a bioengineer developing and using organ-on-a-chip technology to study human health and disease and to streamline the drug development pipeline. Much of his work examines role of mechanobiology and how this can be incorporated into in vitro models to more accurately predict in vivo behaviour. This includes work on osteoarthritis, inflammation, cardiovascular disease, cancer and kidney disease for which he has secured over £5M of recent research funding. Prof Knight is the co-Director of the Queen Mary Centre for Predictive in vitro Models, and co-directed the UK Organ-on-a-chip Technologies Network. He is active in helping to shape policy around the implementation of organ-chip technology and working with industry and other key stake holders.
